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ABSTRACT: Human exposure to engineered nanomaterials (ENMs) is
inevitable due to the plethora of applications for which they are being
manufactured and integrated within. ENMs demonstrate plentiful
advantages in terms of industrial approaches as well as from a consumer
perspective. However, despite such positives, doubts remain over the
human health implications of ENM exposure. In light of the increased
research focus upon the potential effects of ENM exposure to human
health in recent decades, questions still remain regarding the safety of
these highly advanced, precision-tuned physical entities. The risk of
short-term, high-dose exposure to humans is considered relatively low,
although this has formed the direction of the hazard-assessment
community since the turn of the 21st century. However, the possibility
of humans being exposed repeatedly over a long period of time to a low-
dose of ENMs of varying physicochemical characteristics is of significant concern, and thus, industry, government, academic, and
consumer agencies are only now beginning to consider this. Notably, when considering the human health implications of such low-
dose, long-term, repeated exposure scenarios, the impact of ENMs upon the human immune system is of primary importance.
However, there remains a real need to understand the impact of ENMs upon the human immune system, especially the innate
immune system, at all stages of life, given exposure to nanosized particles begins before birth, that is, of the fetus. Therefore, the
purpose of this perspective is to summarize what is currently known regarding ENM exposure of different components of the innate
immune system and identify knowledge gaps that should be addressed if we are to fully deduce the impact of ENM exposure on
innate immune function.
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1. INTRODUCTION
Irrespective of the exposure type toward the human body,
whether it is via inhalation, dermal application, the gastro-
intestinal (GI) tract, direct injection into the circulatory
system, or even via the ocular, immune interactions with
engineered nanomaterials (ENMs) will initially occur through
the innate immune system. The innate immune system is a
diverse array of tissue barriers and specialized cellular roles that
function to limit the damage typically caused by “nonself” and
to facilitate wound healing.1
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Traditionally, the study of immunology has been split into
innate and adaptive (or acquired) immunity. For much of the
20th century, research focused upon identifying and character-
izing components of the adaptive immune system with great
strides made in the understanding of T and B cell biology.
However, since the 1990s, there have been huge advances in
our understanding of innate immunity. This has been achieved
by the systematic identification and characterization of pattern
recognition receptors (PRRs) and their corresponding ligands,
primarily pathogen associated molecular patterns (PAMPs)
but also host-derived danger-associated molecular patterns
(DAMPs), revealing a blueprint for how infection and danger
are sensed at the cellular and molecular level.
Anatomic and physiologic barriers constitute the first line of
defense against not only pathogens but also foreign materials.
When these barriers are overwhelmed or breached, cellular
innate immunity is activated. Mucosal barriers, such as those of
the lung or GI tract, are often the first to encounter exogenous
xenobiotics such as ENMs. In the GI tract, the microbiome has
a central role in maintaining host health by colonizing
biological niches, in principle preventing the potential access
of ENMs to the mucosa and underlying epithelia.1 In the lung,
ENMs are often cleared via robust mucociliary clearance, the
primary innate defense mechanism of the respiratory tract.2
While the integrity of the epithelium and its surfactant layer
should restrict deposition of ENMs into the alveolar region,
ENMs have been demonstrated to reach the underlying
mucosal lamina propria and eventually enter the lymphatic and
portal circulation.3 This requires that ENMs overcome the
physiological processes of the epithelium, where epithelial cell
tight junctions (TJs) should contribute to blocking ENMs
from reaching the underlying lamina propria.4
Epithelial cells also have a repertoire of PRRs. As part of the
innate immune system, epithelial cells are supported by
hematopoietic-derived cells, including monocytes, macro-
phages, dendritic cells (DCs), natural killer (NK) cells, mast
cells, neutrophils and eosinophils, as well as by innate
lymphoid cells (ILCs) and noncellular components such as
cytokines/chemokines, complement proteins, pentraxins, and
collectins. Macrophages and DCs also function as antigen
presenting cells (APCs) linking innate and adaptive immune
responses to, among other things, support the production of
specific antibodies to enhance phagocytosis of foreign materials
by the process of opsonisation on a subsequent encounter.5
PRRs are appositely placed in distinct cellular compartments
to detect PAMPs and DAMPs, constituting an essential early
warning system.6 This range of PRRs includes Toll-like
receptors (TLRs) and the cytosolic nucleotide-binding
oligomerization (NOD)-like receptors (NLRs), retinoic acid-
inducible gene-I (RIG-I)-like receptors, and C-type lectin
receptors (CLRs). It is important to remember that PRRs are
activated not only by PAMPs but by a spectrum of DAMPs
released as a result of cellular or tissue damage including
endogenous proteins, such as high mobility group box 1
(HMGB1) protein, heat shock proteins, nucleic acids, and the
cytokine interleukin (IL)-1α, or by exogenous materials
themselves.7
The breaching of the dense protein/lipid layers (i.e., mucus/
surfactant) at epithelial barriers by pathogens induces an
immediate innate response. Yet, whether ENMs similarly
initiate an innate immune response and what these
mechanisms might be are largely unknown. Recent advances
in nanotechnology are driving a logarithmic increase in the
development and application of ENMs by industry.8 Yet,
understanding of the potential hazard of the inevitable human
exposure to ENMs has not kept pace.9 Reasons for this have
been numerous, including the number and type of ENMs
being manufactured, as well as the experimental approaches
being adopted.10 All of this has instigated ongoing hazard
assessment of ENMs. These are focused predominantly on
toxicological investigations, but elucidation of the long-term
health effects of human ENM exposure requires insight into
how nanomaterials interact with innate immune cells.
The purpose of this perspective therefore is to highlight
current knowledge about the effect of ENMs on the human
innate immune system while indicating key research concepts
for improving our understanding of how ENMs interact with
human immune defense systems. It is important to note that
this article will not cover the human adaptive immune system
or nanomedicine applications toward modulating the innate
immune system. For important reviews on these aspects, the
authors highlight refs 11 and 12 (ENM adaptive immunity and
nanosafety) as well as ref 13 (nanomedicine and the innate
immune system), which adequately cover these areas.
2. BARRIER FUNCTION
It is well-known within the nanosafety community that ENMs
readily interact with epithelial barriers.14 Depending on their
physicochemical properties, inhaled ENMs may deposit in the
airway or alveolar region of the lung, the majority locating to
the alveolar region.15 As noted above, epithelial cell TJs play an
important role in blocking ENMs from entering the underlying
lamina propria4 and regulating paracellular distribution. The
formation of TJs depends on the extra-cellular matrix proteins
such as laminins and collagens and the epithelial cellular
formation expression of zonula occludins (e.g., ZO-1) and
claudins.16 However, as highlighted previously, ENMs can
readily breach epithelial barriers often entering the systemic
circulation.17 In the gut, for example, translocation of ENMs
conjugated with bacterial surface proteins, such as invasin, is
sufficient to confer internalization in mammalian cells.18
Furthermore, due to their hydrophobicity, such specific
ENMs can directly interact with cell membrane lipids,
potentially causing size-dependent, cytotoxic damage in
epithelial cells.19 Oral exposure to silver ENMs alters the
expression of genes associated with GI epithelial TJs, including
claudins and platelet endothelial cell adhesion molecules
(PECAMs), adherens junctions, the NOTCH pathway, and
hemidesmosomes, as well as being associated with an increase
in the cytokine tumor necrosis factor α (TNFα).20 Such a
mechanism could underpin the association between increased
exposure to ENMs and inflammatory bowel diseases such as
ulcerative colitis, a condition associated with dysfunctional
epithelial TJ formation.21 The need to elaborate mechanisms
such as this highlights the need for advanced in vitro systems.22
As an example, alternative in vitro systems to study the
implications of ENM exposure22 can be created by coculture of
the enterocyte-like, microvilli expressing Caco-2 cells and the
goblet cell-like HT29 cell line, which secretes mucus. These
cell lines when cocultured are capable of forming TJs and
display a dense mucus layer representing an epithelial barrier.
While several studies have used this model to investigate the
effect of ENMs, for example, titanium dioxide, these have
yielded conflicting results,23−25 and so further emphasis is
needed to understand the usefulness of these sophisticated
models.26
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Underlying the mucosa is a plethora of immune cells and it
has been realized relatively recently that mucosa function
depends on the interaction between, and communication of,
epithelial and stromal cells with tissue-resident immune cells,
such as macrophages and ILCs, which shape barrier function,
tissue remodelling, and homeostasis.27,28 The discovery of
ILCs has shifted our understanding of the innate immune
response. ILCs are predominantly abundant at the mucosal
surfaces of the lung and intestine and mirror key functions of T
lymphocytes and, although on the whole being beneficial, their
dysregulation is known to contribute to inflammation and
disease pathology.28
ILCs, like tissue-resident macrophages, are likely seeded
during fetal development and maintained in the tissue long-
term. While tissue-resident macrophages, as discussed later, are
continuously replenished by the vasculature, ILCs are
seemingly not,29 although more recent evidence challenges
this concept.30 Although ILCs display a lack of antigen-specific
receptors, ILCs adapt to environmental cues using receptors
for cytokines that are released during tissue damage and
inflammation. ILCs are divided into three main groups, ILC1,
ILC2, and ILC3s, and can be regarded as the innate immune
system’s equivalent of T helper cell subsets Th1, Th2, and
Th17, respectively.30 Similar to natural killer (NK) cells, ILC1s
secrete the cytokine interferon-γ (IFNγ). Accordingly, natural
killer cells are generally grouped with ILC1s; however, for this
review, NK cells will be discussed separately.27
There is limited work on the interaction of ENMs with ILCs
(apart from NK cells). However, there is some evidence of
their impact upon ILC function. For instance, the perinatal
period is a critical time for seeding of innate immune cells,
such as ILCs and tissue-resident macrophages, within
developing organs. Upon prenatal exposure to carbon black
nanoparticles, the postnatal number of CD4−CD8− cells, that
is, non-B or -T lymphocytes, increased in the thymus of male
offspring.31 This cellular population included ILC2s, which
produce traditional Th2 type cytokines (including IL-4, IL-5,
and IL-13) in response to IL-33 and have been associated with
pathology that develops from allergic inflammatory diseases,
for example, asthma.32−34 ILCs are partly regulated by IL-33
from epithelial cells including their potential recruitment from
the bone marrow.30 ENMs, such as titanium, silica, and zinc
(di)oxide carbon nanotubes, are known to exacerbate allergy in
mouse models of allergic airway disease.35−38 Multiwalled
carbon nanotubes (MWCNTs) have been shown to induce
epithelial cells to produce IL-33, which purportedly recruits
ILCs to airways and stimulates production of the Th2 type
cytokine IL-13.39 In addition, pulmonary exposure titanium
dioxide is associated with increased pulmonary ILC2s and a
systemic innate Th2 type response.40 ILC2 immune responses
are characterized by recruitment of important innate effector
cells in allergic disorders such as mast cells, basophils, and
eosinophils.41 Furthermore, epithelial and stromal cells of the
mucosa selectively express the receptor (restricted to cells of a
nonhematopoietic origin) for IL-22, a cytokine produced by
ILC3s complementing the role of Th22 T helper cells. IL-22
may be protective but can also play a pathogenic role in
chronic inflammatory diseases and is associated with
rheumatoid arthritis, inflammatory bowel diseases, and
psoriasis.42 Generally, the role ILCs play in shaping the innate
immune response to ENMs is currently underexplored.
Interestingly, absence of ILCs in patients has been shown to
have no apparent clinical effects including susceptibility to
infection. Therefore, ILCs were proposed to be redundant in
animals with a functioning adaptive immune system (under
conditions of modern medicine and hygiene).43 Nevertheless,
as discussed here, ILCs appear to have roles in the pathology of
sterile inflammatory diseases. Thus, more research is required
to delineate the importance of ILCs in the response to ENMs
and how these responses may have a role in driving pathology.
3. COMPLEMENT SYSTEM
The fate of ENMs in any biological environment is correlated
closely with the formation of a protein corona.44−46 For
example, as ENMs circulate in the blood, their outer surface
rapidly adsorbs biomolecules, such as serum proteins (i.e.,
albumin), which affects the interaction of ENMs with innate
immune cells and their subsequent clearance from the
bloodstream.46,47 Although the formation of a “hard” corona
around the surface of ENMs can be positive in terms of their
potential cytotoxicity,48,49 serum proteins can also “shield”
functionalized nanoparticles from binding to targeted
receptors, causing loss of specificity.50,51
The complement system, an essential humoral component
of innate immunity, was originally characterized for its role in
the destruction and removal of pathogens via the activation of
innate and adaptive immune cells.52 The three pathways of the
complement system, known as the alternative, classical, and
lectin pathways, converge at component C3. This complement
protein is one of the most well reported proteins in the area of
ENM−protein interactions/complex formation.53 Since the
role of complement is to aid the clearance of microbes/
damaged cells via phagocytosis, it is clear that the innate
immune system recognizes ENMs as foreign objects. The
association of C3 has been reported to be a commonly
observed protein on the surface of superparamagnetic iron
oxide nanoparticle (SPION) nanoworms.54 Upon cleavage of
C3, the protein fragment iC3b binds to nonself surfaces and is
an activating ligand of the Type 3 complement receptor (CR3)
on innate immune cells.55 CR3-dependent uptake of opsonized
ENMs may require this activation step. Larger ENMs, such as
latex ENMs, are ingested more readily by IL-4-induced
multinucleated giant cells (MGCs) than unfused macro-
phages.56 Other components of plasma, including IgG and
IgM, can also bind to nonself surfaces and are critical factors in
complement activation.51,57 Material science, through polymer
chemistry, has enabled the coating of ENMs with different
polymers, most often polyethylene glycol (PEG) or zwitter-
ionic polymers,58−65 to form a repulsive barrier to the immune
system, namely phagocytic cells. Nevertheless, adsorption of
proteins to coated ENMs still readily occurs, and this might
actually be useful in avoiding immunosurveillance.62
4. PHAGOCYTOSIS
Binding of C3 to ENMs initiates recognition by phagocyte
receptors that signal for phagocytosis, by neutrophils and
macrophages in particular, and is important for ENM-induced
cytotoxicity.66 The physicochemical properties of ENMs are
well documented to influence the form of active uptake used
by phagocytic cells. Specifically, ENMs with anionic or cationic
surface charges more readily enter phagocytes than ENMs with
a neutral charge.67 Macrophages display increased ENM
uptake upon activation, for example, prestimulation using
lipopolysaccharide (LPS; a prototypic PAMP derived from
Gram negative bacteria), although irrespective of LPS
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stimulation, they play a fundamental role in engulfing and
clearing ENMs.68 Within the nanosafety community, the
interaction between ENMs and phagocytes, especially macro-
phages, has been well described in recent years.69 However, the
impact of ENM exposure on neutrophils is relatively unknown.
While neutrophils have been widely used as a marker of
inflammation following ENM exposure,70 these studies do not
consider the impact of the ENM encounter on neutrophil
function. As highlighted below, this indicates that further focus
upon how neutrophils interact with ENMs is critical to
determine relevance of the prolonged inflammation and the
long-term hazard of ENMs. Alas, even in macrophages, the
specific innate immune pathways that ENMs activate remain
all but undefined. It is important to note, however, that an
inflammatory response initiated by the innate immune
response is primarily a defensive response against a foreign
object (e.g., pathogen) and does not indicate the onset of a
pathological impact. The concept of a prolonged inflammatory
response, above baseline levels, is one that should be
considered as a negative impact and thus one that the
nanosafety community must focus on in terms of ENM hazard
implications.
While it is known that the kinetics of active interaction plays
a significant role, alongside the ENM surface and adsorbed
proteins (as just discussed), the true mechanism of active
entry, as well as intracellular trafficking, which have both been
associated with the hazard noted from ENM-phagocyte
exposure,67 is not fully deduced. Further, it is not a matter
of “read-across” between ENM types since such interaction
and associated impact are considered to be highly specific to
the physicochemical characteristics of ENMs (i.e., size,
geometry, surface coating/chemistry, surface charge).71−76
5. NEUTROPHILS
Neutrophils are the most abundant phagocyte in blood and,
along with tissue-resident macrophages, are considered the first
line of defense once barriers have been penetrated by ENMs.
Granulocytes, such as neutrophils, immobilize and sequester
ENMs, occasionally leading to granuloma formation6 follow-
ing, for example, in vivo exposure to MWNCT.77 In vitro,
neutrophils display size-dependent, rapid internalization of
ENMs40 particularly of polymer coated ENMs adsorbed with
human serum albumin, which increases their entry into
neutrophils two-fold.78 Neutrophils are also activated by
titanium dioxide in vitro,79 and in vivo this is characterized
by a marked neutrophil infiltrate and neutrophilia.80−82
Neutrophils can also form neutrophil extracellular traps
(NETs) in response to exogenous and endogenous DAMPs,
with NET formation (also known as NETosis) dependent on
reactive oxygen species (ROS) formation, and granular
enzymes such as neutrophil elastase (NE) and myeloperox-
idase (MPO).83,84 Notably, MPO is able to degrade ENMs,85
indicating a potential protective effect by the innate immune
system to biodurable/biopersistent ENMs. NETs are formed
by membrane disruption and the translocation of NE and
MPO to the nucleus, initiating histone degradation and the
decondensation and release of chromatin and granular
proteins. NETosis is triggered by ENMs in a size-dependent
manner, initiated by damage to the plasma membrane as well
as lysosomal membranes, resulting in membrane instability.
Neutrophils exposed to ENMs rapidly rupture and release
NETs, for example, within 15 min of contact with gold
ENMs.86 Carbon or polystyrene ENMs induce a size-
dependent formation of NET-like structures. Polyhedral
oligomeric silsesquioxanes (POSS) are readily taken-up by
cells, and their small size and high charge induce NET
formation in a dose-dependent manner.87 Furthermore,
NETosis is not inhibited by caspase inhibitors; therefore, it
might be an apoptosis-independent process.88 A study by
Hwang et al. demonstrated that NETosis, induced by solid
lipid ENMs, was dependent on ROS and calcium.89 NETs,
while initially promoting a pro-inflammatory response, are also
involved in the resolution of chronic inflammation.90 In the
setting of ENM exposure, this might be of benefit as an
immediate short-term inflammatory response triggers NETosis
trapping ENMs, reducing inflammation and limiting tissue
damage in vivo.19 Nanodiamonds induce cellular membrane
damage in vitro and in vivo,19 and the resolution of
nanodiamond-induced inflammation measured as paw edema
in mice was dependent on ROS production and NETosis.
Mice unable to generate NADPH (nicotinamide adenine
dinucleotide phosphate)-dependent ROS failed to initiate
NETosis or resolve inflammation.91 Furthermore, aggregated
NETs also limit inflammation by degrading cytokines and
chemokines.90 However, elucidation of the effects of ENM on
neutrophil structure and function is limited.
6. PATTERN-RECOGNITION RECEPTORS (PRRS)
ENMs may possess pathogen-mimicking properties, resulting
in the activation of PRRs.92 PRRs were initially characterized
for their role in sensing and orchestrating the response to
exogenous pathogens, distinguishing “self” from “nonself”.
However, PRRs have now been firmly established for their role
in detecting DAMPs generated by sterile inflammation, stress
responses, and cell death. PRRs vary in their cellular
localization and binding affinity for DAMPs. TLRs and CLRs
are localized to cellular membranes, including TLRs on
internal endosomal membranes, whereas RLRs or NLRs are
localized to the cytosol. The ten TLRs identified in humans
exist as hetero- or homodimers, composed of ligand-binding
leucine-rich repeats and a toll/IL-1 receptor-like domain
(TIR), which activates cell signaling pathways that culminate
in the production of pro-inflammatory cytokines, TJ
components, and increased mucus secretion from epithelial
cells.93 The NLR family of PRRs activates innate immunity in
response to pathogens, metabolic stress, or sterile inflamma-
tion. For example, NLRP6 regulates goblet cell mucus
secretion at the colonic host−microbial interface,94 whereas
NLRP3 is activated due to disruption of cellular membranes
by, for example, asbestos, silica, or by sensing extracellular ATP
released by injured tissues and cells.95,96 Furthermore,
coactivation of TLRs and NLRP3 leads to the processing of
the cytokine pro-IL-1β into its mature form, a procedure that
requires tightly controlled regulation, due to the tissue-
damaging effects of IL-1β.96
DAMPs, such as nucleic acids, sugars, and lipids, are likely to
adsorb to corona proteins on the surface of ENMs and interact
with PRRs.97 For example, graphene oxide can activate TLR4
in macrophages, inciting a classical inflammatory response and
gold ENMs activate endosomal TLR9 signaling pathways.98,99
This highlights the heterogeneity of ENM interaction with
PRRs, which can have significantly different downstream
effects on the immune response. Further to this single-walled
CNTs (SWCNTs) are neither recognized nor phagocytosed by
phagocytic cells.100 However, other studies report that energy-
independent intracellular trafficking of functionalized CNTs
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occurs after a few hours contact with immune cells, even under
conditions where endocytosis is inhibited.101 Moreover, the
nature of the functional group does not influence whether
CNTs are internalized,101 although coating SWCNTs with
phosphatidylserine reportedly facilitates their uptake by
alveolar macrophages in vitro and in vivo.100 Mass spectrometry
imaging has revealed that the majority of SWNCTs locate to
the kidney and the macrophage rich red pulp region of the
spleen.102 Moreover, a computational study suggests that
CNTs might be recognized as pathogens.103 Extrapolation
from studies of airborne particulate matter (PM), about which
much is already known, might provide insight into the effects
of ENMs. For example, PM exposure is associated with lung
inflammation and chronic respiratory disease and has been
shown to induce a TLR2/TLR4-dependent inflammatory
response in the lung in vivo.104,105
ENM internalization may result in inflammatory responses
initiated by the inflammasome group of protein complexes.
Following from above, airborne PM induced TLR2/TLR4-
dependent inflammatory responses are accompanied by
inflammasome activation and ROS signaling.106 NLRP3
inflammasome activation, triggered by ROS generated by the
NADPH oxidase system, can result in the production of (pro-
)inflammatory cytokines IL-1β and IL-18 from the direct
activation of caspase-1.107 Inflammasomes have been reported
to be activated by both larger particles and ENMs, including
silica,108 amino-functionalized polystyrene ENMs109 and
CNTs,110,111 as well as a range of plasmonic/metal oxide
ENMs, including silver, iron oxide, and titanium diox-
ide.95,112−117 Generally, it is unlikely that inflammasome
activation is a result of discernment of particular ENMs but
rather via the induction of cell stress responses.107,118−120
Thus, ENMs pose a potential indirect effect upon the
inflammasome. Wang et al. demonstrated, in vitro and in
vivo, that glutathione depletion in macrophages exposed to
cellulose nanofibers was involved in ROS generation and a
(pro-)inflammatory response from lung innate immune cells,
that is, epithelial cells.121,122 It has also been reported that
fiber-like aggregates formed by MWCNTs induce the
phenomenon known as “frustrated phagocytosis” in macro-
phages resulting in the production of ROS, NLRP3 activation,
and IL-1β secretion in vitro in a manner similar to
asbestos.123,124 Such results should be taken with extreme
caution, particularly when comparing MWCNTs in general
with asbestos fibers. However, from in vitro and in vivo studies,
it has been reported that ROS-dependent NLRP3 activation
has a role in lung fibrosis.125 NADPH oxidase null mice
showed a marked increase in neutrophils and apoptotic cells in
the lungs in response to SWCNT126 revealing NADPH to have
an important role in orchestrating the transition from acute
inflammation to chronic fibrosis in the lung. Nickel
contamination of MWCNTs was associated with more robust
inflammatory responses in in vitro and in vivo studies. The
nickel contaminated MWCNTs disrupted alveolar macrophage
phagolysosomes inducing NLRP3 activation and the release of
cathepsin B and HMGB1, an endogenous stress DAMP.127,128
Gold ENMs were found to bind to HMGB1 inside lysosomes,
while carbon ENMs stimulated HMGB1 release from macro-
phages.99,129 All of this indicates that ENMs on direct
interaction with innate immune cells, namely macrophages,
can promote the development of chronic inflammation, which
is a significant concern for deducing the safety profile of
ENMs.
7. MACROPHAGES
As evident from the above, the role of the macrophage in the
innate immune response to ENMs is extensive. While they
have deservedly received increased attention in the last two
decades, they still command efforts to understanding immune
interaction with and response to ENMs. Macrophage plasticity
means they can change their function in response to a wide
range of environmental cues, giving rise to subpopulations with
distinct functions. Macrophages are prodigious phagocytic cells
and, as part of their homeostatic role, are responsible for
removing cellular debris and clearing erythrocytes and
apoptotic cells. These immunologically silent homeostatic
processes occur independently of their role in innate
immunity.130 However, cellular debris that occurs as a result
of tissue trauma or stress is often “unsilenced” by the release of
endogenous danger signals, that is, DAMPs, such as nuclear
proteins, heat-shock proteins, histones, and nucleic acids.7
Macrophages detect DAMPs via surface and intracellular
PRRs, and the IL-1 receptor (IL-1R).7 Under these scenarios,
endocytosis by macrophages leads to changes in cell surface
proteins and the induction of inflammatory cytokines and
mediators.130
Macrophages are commonly classified as either classically
activated (M1) or alternatively activated (M2).131 This M1/
M2 classification of macrophages is an oversimplification of the
spectrum of possible phenotypes and should be employed
cautiously as macrophages display dramatic differences in their
physiology and biochemistry132 and can evolve to exhibit
characteristics shared by more than one classification.133
Nevertheless, classically activated M1 macrophages are
generally characterized by increased secretion of inflammatory
mediators and can be induced from monocytes by cytokines
interferon-γ (IFN-γ) and TNF-α.132 In tissue, IFN-γ is
produced at an early stage of the innate immune response by
natural killer (NK) cells, causing macrophages to produce
reactive oxygen and nitrogen species and inflammatory
cytokines.134 In situ, TNF-α will typically be induced by
PRR signaling pathways from the macrophages themselves,
activating macrophage populations in an autocrine or paracrine
manner.133 The importance of TNF-α is apparent in
macrophages as stimulation solely with IFN-γ results in
much less effective clearance of microorganisms. To induce a
more robust response, macrophages can be stimulated with
exogenous TNF-α or PAMPs such as LPS. Activation of PRRs
induces transcription factor pathways, including nuclear factor-
κB (NF-κB), signal transducer and activator of transcription
(STATs), and mitogen activated protein kinases (MAPKs).135
The activation of M1 macrophages should be tightly controlled
as classically activated macrophages produce potentially tissue-
damaging cytokines such as IL-1β, IL-6, and IL-23, which can
result in the expansion of T-helper (TH)17 lymphocytes, which
subsequently secrete IL-17, inducing tissue-recruitment of
neutrophils, leading to tissue damage.136 Alternate granulo-
cytes, including basophils and mast cells, are important for the
production of IL-4, often following tissue injury. Early release
of IL-4 promotes a pool of macrophages, commonly referred to
as alternatively activated macrophages, that function to
promote production of extracellular matrix and wound
healing.131 Macrophages are an important link to adaptive
immunity via antigen processing and presentation. Macro-
phages treated with IL-4 (and/or IL-13) in vitro fail to present
antigen to T-lymphocytes cells and produce little ROS or
Chemical Research in Toxicology pubs.acs.org/crt Perspective
https://dx.doi.org/10.1021/acs.chemrestox.0c00051
Chem. Res. Toxicol. 2020, 33, 1061−1073
1065
inflammatory cytokines. Alternatively activated macrophages
can also be detrimental to the host, being implicated in IL-4
driven fibrosis and experimental asthma.137,138 Macrophage
polarization, however, does not seem to impact their
interaction with ENMs.139 Polarization of macrophages toward
the classically activated M1 phenotype reportedly enhanced
ENM uptake,68 whereas Hoppstadter et al. demonstrated that
alternatively activated differentiated monocytes (dTHP-1)
showed enhanced endocytosis of ENMs.140 Differential uptake
by polarized macrophages might be determined by ENM dose
or the presence of a protein corona.141,142
Functionalized ENMs might even serve to reprogram
macrophage polarization.143 At this time, it is not understood
how ENMs could differentially interact with different macro-
phage phenotypes. This is a key area for future research, in
terms of not only of their safety to human health but also the
potential medical application of ENMs.
Macrophages either originate from embryo progenitors or
differentiate from bone marrow-derived monocytes that
circulate in the blood.49 The majority of the tissue macrophage
cache, including embryo-derived, is replenished over time.49,50
Monocytes migrate from the blood and replenish long-lived
tissue-specific macrophages, known as the mononuclear
phagocyte system (MPS), including osteoclasts (bone),
microglial cells (central nervous system), alveolar cells
(lungs), Kupffer cells (liver), and also within the spleen and
GI tract. However, the frequency at which these pools are
replenished depends on the tissue type. For example, the
turnover of embryo derived alveolar macrophages in the lung
may take months to years, whereas in the gut, macrophages are
turned over rapidly, within days to weeks.132 There is also
evidence that local proliferation of tissue-resident macrophages
occurs, sustaining populations of mature macrophages in
tissue.144 This leads to the question of whether tissue
macrophage function changes as the macrophage population
is replenished and more critically for the purposes of this
review how ENMs might impact upon such potentially
changed macrophage populations.
8. DENDRITIC CELLS
Although it is clear that further research is needed in terms of
deducing the role of macrophage−ENM interactions, the same
can be said for DC−ENM interactions. Notable reviews about
DCs and their interaction with ENMs have been published
recently.145 However, as these cells are critical in bridging the
innate and adaptive immune systems, it is essential to note
some key findings here. DCs exist in an immature state in the
periphery, becoming mature DCs by the recognition of
components of the innate immune system, that is, antigens/
PAMPs/DAMPs, loss of their endocytic and phagocytic
receptors, and migration to the lymphoid organs for T cell
priming.146 ENMs, such as gold ENMs, readily accumulate in
DCs of the spleen after intravenous injection.147 Different
surface modifications of gold ENMs affected DC viability and
their inflammatory response.148 In contrast, DCs exposed to
silver ENMs have increased ROS production, decreased
viability, but no change was found in inflammatory cytokine
production.149 Negatively charged PEG coated iron (II, III)
oxide ENMs activate the peroxisome proliferator-activated
receptor γ coactivator 1α (PGC1α) pathway in DCs, inducing
mitochondrial instability via decreased autophagy.150 Further-
more, NOD ligands encapsulated into poly(lactic acid) (PLA)
biodegradable nanocarriers were efficiently taken up by DCs
inducing maturation and inflammatory cytokine secretion.151
This again highlights how the physicochemical characteristics
of ENMs determine how ENMs are recognized and drive the
functional effects on the innate immune system. Whether DCs
identify and treat ENMs as antigens for processing and
presentation to T cells remains to be determined. This is
particularly important when considering the many approaches
encompassed under the umbrella term of nanomedicine.
9. NATURAL KILLER CELLS
Another critical cell type linking the innate and adaptive
immune systems is a group 1 ILC, the NK cell.152,153 NK cells
readily interact with DCs, macrophages, T cells, and epithelial
and endothelial cells. NK cells are abundant in blood but exert
their function primarily in tissues including secondary
lymphoid organs. NK cells are important sentinel immune
cells at mucosal surfaces, including the nasal cavity and GI
tract, and make up around 10% of lymphocytes in the
lung.154,155 NK cells can induce direct antibody-independent
destruction of stressed, abnormal, or virally infected cells via
release of granule-dependent cytotoxic mediators such as
granzyme B and perforin or via the Fas ligand-mediated (death
receptor) pathway or engagement of TNF receptors, leading to
apoptosis.156 NK cell activation is finely tuned resulting in the
release of immune activating cytokines, such as IFN-γ, IL-4 and
TNF-α, which can act on other innate immune cells, including
DCs157 and epithelial cells158 and on adaptive immune cells,
such as T cells.156 NK cell activation is orchestrated by surface
expression of inhibitory and activating receptors or cytokines
including IL-2, IL-12, IL-15, and IL-18. The major inhibitory
receptors are specific for human leukocyte antigen (HLA) class
I molecules (i.e., major histocompatibility complex (MHC)),
preventing NK cells from attacking autologous cells.
NK cells can be grouped into cytokine secreting or cytotoxic
subgroups by the expression of the cell adhesion receptor
CD56 or the cytotoxic receptors CD16, respectively.159
Because of their abundance in blood and location at mucosal
surfaces, NK cells, in principle, can rapidly interact with
exogenous ENMs. Exposure of blood-derived NK cells to silver
ENMs reduced their viability and cytotoxic potential. This
seemed to be by changing the relative abundance of inhibitory
and activating receptors, increased expression of inhibitory
CD159a, which binds to HLA class I molecules, and activating
CD314, which binds to ligands on epithelial cell surfaces,
accompanied by decreased expression of activating CD16.160 A
similar phenotype, reduced viability and reduced CD16
expression, was seen when NK cells were exposed to uncoated
zinc oxice ENMs.161,162 However, in vivo studies with silver
ENMs conflict with these results, but this might reflect varied
experimental approaches, that is, routes of administration and
types of ENMs.163,164 Nonetheless, in the study by Muller et
al., silver ENMs did not induce the oxidative stress or the
inflammation observed in lung cells in vitro.165 However,
Andersson-Willman et al. showed no effect of titanium dioxide
on NK cells. In vivo, lung exposure to titanium dioxide induced
a transient increase in an NK cell population, marked by an
increase in T cell-activating cytokine profile, without associated
lung pathology of epithelial injury or lung fibrosis.166 This may
indicate that early ENM exposure initiates an innate immune
response to which NK cells contribute, potentially culminating
in a T cell adaptive immune response. As with all of the cell
types discussed herein, there is a fundamental need for more
research about NK cell interaction with ENMs.
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10. MODELS OF THE INNATE IMMUNE SYSTEM
As within the nanosafety community as a whole, primary
research into this area previously has focused upon in vivo
models (i.e., rodents) or ex vivo cell systems (i.e., PBMCs)
with few assessments using alternative models (i.e., in vitro
systems). However, recent years have seen more in vitro studies
on the innate immune response conducted, albeit using cell
lines, that is, A549/Calu-3 (lung), Caco-2 (GI tract),167 or
HepG2 (liver),168 or continuing with the ex vivo or modeled
“primary” cell-type (e.g., monocyte-derived macrophages). As
across the nanosafety arena, it is important to focus upon
alternative models and approaches to deduce the mechanistic,
biological implications of ENM exposure. However, using only
one cell type does not replicate the complex physiology of
tissue barriers or the innate immune system in vivo. Although
advanced in vitro systems are available, it is important to note
that many multicellular systems often neglect to include
important immune cell populations, although key examples
where this has been achieved are available.169 The interaction
between different innate immune cells is relatively unexplored
yet requires attention to determine how the interplay of these
cells upon ENM exposure and how this might affect other cell
types within the biological system/environment. There are also
novel systems focusing on specific sections of organ anatomy
that have been largely ignored to date. For example, there have
been attempts to create an in vitro model of the nasal
epithelium since this will be the first tissue interacting with
ENMs following their inhalation.170 Several approaches are
being attempted to establish advanced, nonstatic alternative
models to assess the innate immune response to ENMs.
Recently, for example, Li et al. have developed a perfusable 3D
human microvessel network within a microfluidic device,
which partly portrays the physiological response of human
vessels.82 These advances are imperative if we are to fully
elucidate the effects of ENM exposure on the innate immune
system and thereby human health.
11. SUMMARY AND FUTURE CONSIDERATIONS
In summary, the innate immune system is one of the key pillars
of host defense toward foreign bodies that includes xenobiotics
and pathogens. It intelligently directs specific cell subsets to
interact with, and if necessary null these threats across all
organs of the entire human body. It is, as highlighted
throughout this perspective, pivotal to any adaptive immune
response and thus governs such a response meticulously to
provide an efficient and effective response to these foreign,
nonself objects in the human body. Alas, despite the clear
growth within the nanosafety field of understanding the impact
of ENMs upon the innate immune system, many knowledge
gaps remain. Specific examples of these knowledge gaps relate
to:
• The precise manner in which ENMs interact/bind with
key innate immune cells. It is understood that the
manner of entry into (immune) cells can contribute
toward the hazard noted. To date, the precise entry
mechanism has not been defined for ENMs, albeit
elucidated for some. Nonetheless, the receptor-mediated
approaches are not fully deduced. How ENMs may
interact/bind with specific PRRs, on specific innate
immune cells, will allow not only the entry mechanism
to be noted but also the pathway and signaling cascades
that might be relevant to how the cell will, potentially,
process the ENM. Thus, entry mechanisms are simply
not enough, but specific receptor-binding knowledge is
the next step forward in understanding the ENM−
immune cell interaction.
• Understanding how ENMs and specifically how their
different physicochemical characteristics may impact
upon the structure and function of key innate immune
cells (i.e., macrophages, neutrophils, DCs, and NK cells).
• Further research must be given toward understanding
the above focus points on the currently less studied
leukocyte populations (i.e., lymphocytes (both T- and B-
cells), eosinophils, basophils, and mast cells) and how
ENMs interact with them (potentially impacting their
structure and function).
• Deducing how the different (innate) immune cells
interplay with one another, in different organs, following
ENM exposure/interaction, and how they respond to
ENM exposure. This approach befits advanced in vitro
approaches using multicellular models as well as
dynamic, fluid-flow systems to allow effective mimicking
of the in vivo scenario.
• In combination with the above approach, understanding
the complete signaling cascade, following ENM
exposure, is essential. Measuring one soluble mediator
(e.g., cytokine/chemokine) is not sufficient. Knowledge
as to how the immune response adapts to the initial
ENM exposure over time, and relative to dose, and then
how this impacts upon cell/tissue/organ structure and
function are now necessary requirements to deduce the
complete impact of ENMs upon the innate immune
system.
It is imperative that research is focused upon these areas
since it will allow for the elucidation of vital information about
both detrimental and beneficial effects of ENM exposure on
host defense mechanisms and inform realistic low-dose, long-
term, repeated exposure scenarios. Only then will it be possible
to realize the advantages of ENMs across the plethora of
different disciplines and applications, most notably nano-
medicine.
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